As displayed in Fig. 2E–F, higher NRAS, p-ERK1/2, and Cdc25a expression could be observed in LLC and A549, confirming that the NRAS signaling pathway was activated in lung cancer cells. This evidence concerns the gene MAPK3 and lung cancer.